<?xml version='1.0' encoding='utf-8'?>
<document id="25008118"><sentence text="Physiologically based pharmacokinetic modeling for assessing the clinical drug-drug interaction of alisporivir." /><sentence text="Alisporivir is a novel cyclophilin-binding molecule with potent anti-hepatitis C virus (HCV) activity"><entity charOffset="0-11" id="DDI-PubMed.25008118.s2.e0" text="Alisporivir" /></sentence><sentence text=" In vitro data from human liver microsomes suggest that alisporivir is a substrate and a time-dependent inhibitor (TDI) of CYP3A4" /><sentence text=" The aim of the current work was to develop a novel physiologically based pharmacokinetic (PBPK) model to quantitatively assess the magnitude of CYP3A4 mediated drug-drug interactions with alisporivir as the substrate or victim drug" /><sentence text=" Towards that, a Simcyp PBPK model was developed by integrating in vitro data with in vivo clinical findings to characterize the clinical pharmacokinetics of alisporivir and further assess the magnitude of drug-drug interactions" /><sentence text=" Incorporated with absorption, distribution, elimination, and TDI data, the model accurately predicted AUC, Cmax, and tmax values after single or multiple doses of alisporivir with a prediction deviation within ± 32%"><entity charOffset="164-175" id="DDI-PubMed.25008118.s6.e0" text="alisporivir" /></sentence><sentence text=" The model predicted an alisporivir AUC increase by 9" /><sentence text="4-fold and a decrease by 86% when alisporivir was co-administrated with ketoconazole (CYP3A4 inhibitor) or rifampin (CYP3A4 inducer), respectively"><entity charOffset="72-84" id="DDI-PubMed.25008118.s8.e0" text="ketoconazole" /><entity charOffset="107-115" id="DDI-PubMed.25008118.s8.e1" text="rifampin" /><pair ddi="false" e1="DDI-PubMed.25008118.s8.e0" e2="DDI-PubMed.25008118.s8.e0" /><pair ddi="false" e1="DDI-PubMed.25008118.s8.e0" e2="DDI-PubMed.25008118.s8.e1" /></sentence><sentence text=" Predictions were within ± 20% of the observed changes" /><sentence text=" In conclusion, the PBPK model successfully predicted the alisporivir PK and the magnitude of drug-drug interactions" /><sentence text="" /></document>